The gene-editing sector has a bright future ahead, but does that make every company in that market a buy?
News & Analysis: Sangamo Therapeutics
SGMO earnings call for the period ending June 30, 2019.
Pipeline progress was the big story in Q2 for this clinical-stage biotech.
The biotech's gene therapy to treat hemophilia A looks promising.
Sangamo Therapeutics reported positive data on its gene therapy for hemophilia, and CannTrust Holdings received a noncompliance report from Canadian authorities.
Results released late on Friday gave investors a reason to cheer.
SGMO earnings call for the period ending March 31, 2019.
The biopharma announced first-quarter 2019 operating results.
The biotech's revenue fell. But it still managed to beat the consensus Wall Street earnings estimate.
The grandaddy of gene-editing stocks recently provided an encouraging update, but it isn't the only experimental hemophilia therapy out there.